News
News and events as they happenKaterzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, is Now Commercially Available for Pediatric Patients 6 Years of Age and Older
WOBURN, Mass. (September 25, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that Katerzia (amlodipine) Oral Suspension, 1...
Azurity All-Hands Company Meeting
WOBURN, Mass. (September 11, 2019) - This September two companies met and became one, Azurity Pharmaceuticals is the beginning of that new family. This was a time to meet and get to know each other and build as an organization. The combination of the two legacy...
FDA Approves Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older
WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that the U.S. Food and Drug Administration (FDA) has...
Resources
Azurity Pharmaceuticals™, Inc. was formerly known as CutisPharma®, Inc., parent company of Silvergate Pharmaceuticals™, Inc. Product labeling may reflect Azurity, CutisPharma or Silvergate.
All product imagery is for representation purposes only and may not include actual labels.
© 2020 Azurity Pharmaceuticals™, Inc. All Rights Reserved. WEB-AZ-1
